36.01
price down icon3.21%   -1.0712
 
loading
Schlusskurs vom Vortag:
$37.08
Offen:
$37.2
24-Stunden-Volumen:
248.37K
Relative Volume:
0.57
Marktkapitalisierung:
$1.32B
Einnahmen:
$154.15M
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-37.51
EPS:
-0.96
Netto-Cashflow:
$-20.74M
1W Leistung:
+4.42%
1M Leistung:
+17.06%
6M Leistung:
+3.88%
1J Leistung:
+41.97%
1-Tages-Spanne:
Value
$35.27
$37.59
1-Wochen-Bereich:
Value
$33.33
$38.09
52-Wochen-Spanne:
Value
$20.85
$59.23

Harrow Inc Stock (HROW) Company Profile

Name
Firmenname
Harrow Inc
Name
Telefon
615.733.4731
Name
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Name
Mitarbeiter
382
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
HROW's Discussions on Twitter

Vergleichen Sie HROW mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
HROW
Harrow Inc
35.95 1.31B 154.15M -33.58M -20.74M -0.96
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
149.38 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.54 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.605 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.18 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.48 13.43B 2.99B 1.21B 1.13B 25.06

Harrow Inc Stock (HROW) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-11 Eingeleitet Cantor Fitzgerald Overweight
2025-06-12 Eingeleitet BTIG Research Buy
2025-06-10 Eingeleitet William Blair Outperform
2025-02-06 Eingeleitet H.C. Wainwright Buy
2024-12-04 Bestätigt B. Riley Securities Buy
2024-04-11 Eingeleitet Craig Hallum Buy
2022-09-08 Fortgesetzt B. Riley Securities Buy
2021-10-14 Fortgesetzt B. Riley Securities Buy
2021-09-24 Eingeleitet Aegis Capital Buy
2021-07-02 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Harrow Inc Aktie (HROW) Neueste Nachrichten

pulisher
09:12 AM

Is Harrow Inc. a good long term investmentRapid capital growth - jammulinksnews.com

09:12 AM
pulisher
07:22 AM

What analysts say about Harrow Inc. stockDynamic capital growth - jammulinksnews.com

07:22 AM
pulisher
Jul 21, 2025

What drives Harrow Inc. stock priceMarket-beating returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Harrow Inc. Stock Analysis and ForecastMassive wealth growth - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View

Jul 20, 2025
pulisher
Jul 19, 2025

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

Jul 19, 2025
pulisher
Jul 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent

Jul 18, 2025
pulisher
Jul 18, 2025

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare

Jul 18, 2025
pulisher
Jul 18, 2025

Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook

Jul 18, 2025
pulisher
Jul 17, 2025

Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency

Jul 17, 2025
pulisher
Jul 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com

Jul 17, 2025
pulisher
Jul 17, 2025

Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView

Jul 17, 2025
pulisher
Jul 17, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com Australia

Jul 17, 2025
pulisher
Jul 17, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire

Jul 17, 2025
pulisher
Jul 17, 2025

Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

(HROW) Trading Report - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com

Jul 14, 2025
pulisher
Jul 13, 2025

Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World

Jul 13, 2025
pulisher
Jul 11, 2025

Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha

Jul 11, 2025
pulisher
Jul 11, 2025

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 11, 2025
pulisher
Jul 11, 2025

Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha

Jul 11, 2025
pulisher
Jul 11, 2025

Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jul 09, 2025

Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha

Jul 09, 2025

Finanzdaten der Harrow Inc-Aktie (HROW)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Harrow Inc-Aktie (HROW) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Opaleye Management Inc.
10% Owner
Jun 09 '25
Sale
30.37
15,204
461,794
105,000
Opaleye Management Inc.
10% Owner
Jun 03 '25
Sale
30.04
3,000
90,116
122,000
Opaleye Management Inc.
10% Owner
Jun 04 '25
Sale
30.02
1,796
53,907
120,204
Opaleye Management Inc.
10% Owner
May 12 '25
Sale
25.90
10,000
258,959
130,000
Opaleye Management Inc.
10% Owner
May 13 '25
Sale
26.59
5,000
132,945
125,000
BOLL ANDREW R.
Chief Financial Officer
Apr 03 '25
Option Exercise
0.00
346,500
0
914,589
SAHAREK JOHN P.
CEO & President, ImprimisRx
Apr 03 '25
Option Exercise
0.00
277,200
0
576,863
BAUM MARK L
Chief Executive Officer
Apr 03 '25
Option Exercise
0.00
762,300
0
2,899,825
Opaleye Management Inc.
10% Owner
Mar 18 '25
Sale
30.01
5,000
150,055
140,000
Opaleye Management Inc.
10% Owner
Mar 18 '25
Sale
29.64
5,000
148,200
145,000
$71.33
price down icon 0.37%
$14.86
price up icon 1.19%
$8.98
price up icon 0.45%
drug_manufacturers_specialty_generic RDY
$14.40
price down icon 1.07%
$133.00
price up icon 0.51%
$298.11
price up icon 1.62%
Kapitalisierung:     |  Volumen (24h):